SUPPLEMENT

Q4 2022 — Other Financial Disclosures

Q4 2022PDF · 18 pages771 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 8
Table 3a: Supplemental Sales Reconciliation 9
Table 4: Condensed Consolidated Statement of Earnings - QTD 10
Table 5: Condensed Consolidated Statement of Earnings - YTD 11
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 12
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 13
Table 8: Non-GAAP Adjusted Net Earnings 14
Table 9: Non-GAAP IBT by Segment - QTD 15
Table 10: Non-GAAP IBT by Segment - YTD 16
Table 11: Non-GAAP P&L Reconciliation 17
Fourth Quarter 2022
Other Financial Disclosures
Table of Contents

-- 1 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
segment of business
Consumer Health (1)
U.S. 1,696	$ 1,529 10.9 % 10.9 - 6,599	$ 6,516 1.3 % 1.3 -
International 2,071 2,199 (5.8) 3.2 (9.0) 8,354 8,519 (1.9) 5.3 (7.2)
3,767 3,728 1.0 6.4 (5.4) 14,953 15,035 (0.5) 3.6 (4.1)
Pharmaceutical (1)
U.S. 7,375 7,418 (0.6) (0.6) - 28,604 27,954 2.3 2.3 -
International 5,788 6,799 (14.9) (4.5) (10.4) 23,959 23,726 1.0 11.9 (10.9)
13,163 14,217 (7.4) (2.5) (4.9) 52,563 51,680 1.7 6.7 (5.0)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
U.S. 7,375 7,205 2.4 2.4 - 28,484 27,320 4.3 4.3 -
International 5,099 5,394 (5.5) 6.0 (11.5) 21,900 21,975 (0.3) 10.3 (10.6)
12,474 12,599 (1.0) 3.9 (4.9) 50,384 49,295 2.2 6.9 (4.7)
MedTech (2)
U.S. 3,445 3,216 7.1 7.1 - 13,377 12,686 5.4 5.4 -
International 3,331 3,643 (8.6) 2.9 (11.5) 14,050 14,374 (2.3) 6.9 (9.2)
6,776 6,859 (1.2) 4.9 (6.1) 27,427 27,060 1.4 6.2 (4.8)
U.S. 12,516 12,163 2.9 2.9 - 48,580 47,156 3.0 3.0 -
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706 24,804 (4.4) 0.9 (5.3) 94,943 93,775 1.3 6.1 (4.8)
U.S. 12,516 11,950 4.7 4.7 - 48,460 46,522 4.2 4.2 -
International 10,501 11,236 (6.5) 4.4 (10.9) 44,304 44,868 (1.3) 8.2 (9.5)
Worldwide excluding COVID-19 Vaccine (3) 23,017	$ 23,186 (0.7) % 4.6 (5.3) 92,764	$ 91,390 1.5 % 6.2 (4.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(3) Refer to supplemental sales reconciliation schedule.
Page 1 of 17
FOURTH QUARTER
Percent Change
TWELVE MONTHS
(2) Previously referred to as Medical Devices.
Percent Change

-- 2 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,516	$ 12,163 2.9 % 2.9 - 48,580	$ 47,156 3.0 % 3.0 -
Europe 5,816 6,925 (16.0) (6.3) (9.7) 23,449 23,594 (0.6) 11.0 (11.6)
Western Hemisphere excluding U.S. 1,545 1,459 5.9 11.8 (5.9) 6,125 5,750 6.5 10.2 (3.7)
Asia-Pacific, Africa 3,829 4,257 (10.0) 3.1 (13.1) 16,789 17,275 (2.8) 6.2 (9.0)
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706	$ 24,804 (4.4) % 0.9 (5.3) 94,943	$ 93,775 1.3 % 6.1 (4.8)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
Page 2 of 17
FOURTH QUARTER
Percent Change
TWELVE MONTHS
Percent Change

-- 3 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 754	$ 633 18.9% 18.9% - 2,782	$ 2,594 7.3% 7.3% -
Intl 815 811 0.6% 9.6% -9.0% 3,249 3,034 7.1% 14.5% -7.4%
WW 1,569 1,444 8.6% 13.7% -5.1% 6,031 5,627 7.2% 11.2% -4.0%
SKIN HEALTH / BEAUTY
US 573 538 6.5% 6.5% - 2,337 2,400 -2.6% -2.6% -
Intl 515 546 -5.6% 4.4% -10.0% 2,015 2,141 -5.9% 2.2% -8.1%
WW 1,088 1,084 0.4% 5.4% -5.0% 4,352 4,541 -4.2% -0.4% -3.8%
ORAL CARE
US 164 159 3.3% 3.3% - 635 637 -0.3% -0.3% -
Intl 207 246 -16.0% -8.1% -7.9% 871 1,008 -13.6% -7.4% -6.2%
WW 370 405 -8.4% -3.7% -4.7% 1,505 1,645 -8.5% -4.7% -3.8%
BABY CARE
US 93 90 3.4% 3.4% - 357 378 -5.5% -5.5% -
Intl 264 309 -14.6% -7.4% -7.2% 1,104 1,188 -7.1% -1.4% -5.7%
WW 356 399 -10.6% -5.0% -5.6% 1,461 1,566 -6.7% -2.4% -4.3%
WOMEN'S HEALTH
US 4 4 15.6% 15.6% - 13 13 1.7% 1.7% -
Intl 217 230 -5.7% 4.4% -10.1% 891 905 -1.5% 7.1% -8.6%
WW 220 233 -5.5% 4.6% -10.1% 904 917 -1.5% 7.0% -8.5%
WOUND CARE / OTHER
US 109 106 3.3% 3.3% - 475 495 -4.0% -4.0% -
Intl 54 57 -7.5% 2.9% -10.4% 224 243 -8.0% -3.4% -4.6%
WW 163 164 -0.5% 3.1% -3.6% 700 739 -5.3% -3.8% -1.5%
TOTAL CONSUMER HEALTH
US 1,696 1,529 10.9% 10.9% - 6,599 6,516 1.3% 1.3% -
Intl 2,071 2,199 -5.8% 3.2% -9.0% 8,354 8,519 -1.9% 5.3% -7.2%
WW 3,767	$ 3,728 1.0% 6.4% -5.4% 14,953	$ 15,035 -0.5% 3.6% -4.1%
See footnotes at end of schedule Page 3 of 17
% Change % Change

-- 4 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
IMMUNOLOGY
US 2,805	$ 2,912 -3.6% -3.6% - 11,036	$ 10,843 1.8% 1.8% -
Intl 1,312 1,443 -9.1% 2.1% -11.2% 5,899 5,907 -0.1% 10.3% -10.4%
WW 4,118 4,355 -5.4% -1.8% -3.6% 16,935 16,750 1.1% 4.8% -3.7%
REMICADE
US 318 511 -37.7% -37.7% - 1,417 2,019 -29.8% -29.8% -
US Exports (4) 41 39 5.1% 5.1% - 204 236 -13.6% -13.6% -
Intl 116 214 -45.9% -41.3% -4.6% 722 935 -22.8% -18.7% -4.1%
WW 475 764 -37.8% -36.5% -1.3% 2,343 3,190 -26.6% -25.3% -1.3%
SIMPONI / SIMPONI ARIA
US 280 287 -2.2% -2.2% - 1,166 1,127 3.5% 3.5% -
Intl 220 271 -18.6% -7.4% -11.2% 1,017 1,148 -11.4% -1.4% -10.0%
WW 501 559 -10.2% -4.7% -5.5% 2,184 2,276 -4.0% 1.0% -5.0%
STELARA
US 1,621 1,542 5.2% 5.2% - 6,388 5,938 7.6% 7.6% -
Intl 764 792 -3.5% 8.1% -11.6% 3,335 3,196 4.4% 15.7% -11.3%
WW 2,386 2,334 2.3% 6.2% -3.9% 9,723 9,134 6.5% 10.4% -3.9%
TREMFYA
US 541 528 2.5% 2.5% - 1,844 1,503 22.7% 22.7% -
Intl 211 165 27.5% 44.5% -17.0% 824 624 32.0% 47.8% -15.8%
WW 752 693 8.5% 12.5% -4.0% 2,668 2,127 25.4% 30.1% -4.7%
OTHER IMMUNOLOGY
US 3 6 -53.5% -53.5% - 17 21 -18.4% -18.4% -
Intl 0 0 * * * 0 3 * * *
WW 3 6 -53.3% -53.3% 0.0% 17 24 -28.2% -28.2% 0.0%
INFECTIOUS DISEASES
US 414 614 -32.6% -32.6% - 1,680 2,249 -25.3% -25.3% -
Intl 1,127 1,818 -38.0% -31.0% -7.0% 3,769 3,576 5.4% 17.3% -11.9%
WW 1,540 2,431 -36.6% -31.4% -5.2% 5,449 5,825 -6.5% 0.8% -7.3%
COVID-19 VACCINE
US 0 213 * * - 120 634 -81.1% -81.1% -
Intl 689 1,405 -50.9% -45.0% -5.9% 2,059 1,751 17.6% 32.1% -14.5%
WW 689 1,619 -57.4% -52.2% -5.2% 2,179 2,385 -8.6% 2.0% -10.6%
EDURANT / rilpivirine
US 9 10 1.2% 1.2% - 36 41 -10.8% -10.8% -
Intl 281 220 27.6% 39.2% -11.6% 972 953 2.0% 12.7% -10.7%
WW 290 230 26.5% 37.6% -11.1% 1,008 994 1.5% 11.8% -10.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 398 380 4.7% 4.7% - 1,494 1,508 -1.0% -1.0% -
Intl 95 135 -29.5% -20.5% -9.0% 449 575 -21.9% -13.4% -8.5%
WW 493 515 -4.3% -1.9% -2.4% 1,943 2,083 -6.7% -4.4% -2.3%
OTHER INFECTIOUS DISEASES
US 6 11 -47.1% -47.1% - 30 66 -55.5% -55.5% -
Intl 61 57 7.3% 18.0% -10.7% 289 297 -2.6% 3.6% -6.2%
WW 67 68 -1.6% 7.4% -9.0% 318 363 -12.3% -7.2% -5.1%
Page 4 of 17
% Change % Change

-- 5 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
NEUROSCIENCE
US 912 899 1.4% 1.4% - 3,570 3,347 6.7% 6.7% -
Intl 825 890 -7.2% 3.3% -10.5% 3,323 3,641 -8.7% 0.4% -9.1%
WW 1,737 1,789 -2.8% 2.4% -5.2% 6,893 6,988 -1.4% 3.4% -4.8%
CONCERTA / Methylphenidate
US 37 55 -34.3% -34.3% - 151 172 -12.5% -12.5% -
Intl 131 123 6.5% 20.3% -13.8% 493 495 -0.4% 9.9% -10.3%
WW 168 178 -6.2% 3.4% -9.6% 644 667 -3.5% 4.1% -7.6%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 678 668 1.8% 1.8% - 2,714 2,550 6.5% 6.5% -
Intl 329 361 -8.8% 2.7% -11.5% 1,426 1,472 -3.1% 7.8% -10.9%
WW 1,008 1,029 -2.0% 2.1% -4.1% 4,140 4,022 3.0% 6.9% -3.9%
RISPERDAL CONSTA
US 62 77 -19.4% -19.4% - 257 287 -10.4% -10.4% -
Intl 50 63 -21.5% -9.7% -11.8% 228 305 -25.3% -15.5% -9.8%
WW 112 140 -20.4% -15.0% -5.4% 485 592 -18.1% -13.0% -5.1%
OTHER NEUROSCIENCE
US 134 99 35.5% 35.5% - 447 338 32.4% 32.4% -
Intl 315 342 -7.7% 0.3% -8.0% 1,176 1,368 -14.1% -7.5% -6.6%
WW 449 441 2.0% 8.2% -6.2% 1,623 1,706 -4.9% 0.4% -5.3%
ONCOLOGY
US 1,857 1,594 16.5% 16.5% - 6,930 5,958 16.3% 16.3% -
Intl 2,069 2,184 -5.3% 6.8% -12.1% 9,052 8,590 5.4% 17.3% -11.9%
WW 3,927 3,778 3.9% 10.9% -7.0% 15,983 14,548 9.9% 16.9% -7.0%
DARZALEX
US 1,139 867 31.4% 31.4% - 4,210 3,169 32.8% 32.8% -
Intl 944 778 21.3% 36.7% -15.4% 3,767 2,854 32.0% 47.0% -15.0%
WW 2,083 1,645 26.6% 33.9% -7.3% 7,977 6,023 32.4% 39.5% -7.1%
ERLEADA
US 275 235 17.2% 17.2% - 968 813 19.2% 19.2% -
Intl 266 149 78.0% 97.8% -19.8% 913 478 * * *
WW 541 384 40.9% 48.6% -7.7% 1,881 1,291 45.7% 53.0% -7.3%
IMBRUVICA
US 318 436 -27.0% -27.0% - 1,390 1,747 -20.4% -20.4% -
Intl 547 626 -12.5% -2.0% -10.5% 2,394 2,622 -8.7% 1.0% -9.7%
WW 866 1,062 -18.5% -12.3% -6.2% 3,784 4,369 -13.4% -7.6% -5.8%
ZYTIGA / abiraterone acetate
US 20 23 -14.3% -14.3% - 74 119 -37.8% -37.8% -
Intl 250 525 -52.4% -44.8% -7.6% 1,696 2,178 -22.1% -12.3% -9.8%
WW 270 548 -50.8% -43.6% -7.2% 1,770 2,297 -22.9% -13.6% -9.3%
OTHER ONCOLOGY
US 106 34 * * - 289 110 * * -
Intl 63 106 -41.1% -33.1% -8.0% 283 458 -38.3% -31.6% -6.7%
WW 168 140 20.6% 26.7% -6.1% 571 568 0.6% 6.0% -5.4%
Page 5 of 17
% Change % Change

-- 6 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 610 587 3.9% 3.9% - 2,346 2,365 -0.8% -0.8% -
Intl 261 264 -1.3% 13.5% -14.8% 1,071 1,085 -1.3% 11.2% -12.5%
WW 870 851 2.3% 6.9% -4.6% 3,417 3,450 -1.0% 3.0% -4.0%
OPSUMIT
US 305 286 7.0% 7.0% - 1,132 1,147 -1.3% -1.3% -
Intl 156 162 -3.7% 11.0% -14.7% 651 672 -3.2% 9.3% -12.5%
WW 461 448 3.1% 8.4% -5.3% 1,783 1,819 -2.0% 2.6% -4.6%
UPTRAVI
US 280 264 6.3% 6.3% - 1,104 1,056 4.5% 4.5% -
Intl 56 46 20.4% 33.3% -12.9% 218 181 20.4% 32.4% -12.0%
WW 336 310 8.4% 10.3% -1.9% 1,322 1,237 6.9% 8.6% -1.7%
OTHER PULMONARY HYPERTENSION
US 24 38 -35.5% -35.5% - 110 163 -32.3% -32.3% -
Intl 48 56 -12.2% 4.4% -16.6% 202 232 -12.8% 0.3% -13.1%
WW 73 94 -21.7% -11.8% -9.9% 313 395 -20.8% -13.1% -7.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 776 813 -4.4% -4.4% - 3,042 3,192 -4.7% -4.7% -
Intl 194 200 -3.4% 5.7% -9.1% 845 927 -8.9% -1.7% -7.2%
WW 971 1,013 -4.2% -2.4% -1.8% 3,887 4,119 -5.6% -4.0% -1.6%
XARELTO
US 667 644 3.4% 3.4% - 2,473 2,438 1.4% 1.4% -
Intl - - - - - - - - - -
WW 667 644 3.4% 3.4% - 2,473 2,438 1.4% 1.4% -
INVOKANA / INVOKAMET
US 29 59 -51.3% -51.3% - 193 308 -37.4% -37.4% -
Intl 62 60 2.3% 11.2% -8.9% 255 254 0.1% 7.3% -7.2%
WW 91 120 -24.1% -19.6% -4.5% 448 563 -20.4% -17.2% -3.2%
OTHER
US 81 110 -25.7% -25.7% - 376 446 -15.5% -15.5% -
Intl 132 140 -5.9% 3.3% -9.2% 590 673 -12.3% -5.1% -7.2%
WW 213 250 -14.6% -9.4% -5.2% 966 1,119 -13.6% -9.3% -4.3%
TOTAL PHARMACEUTICAL
US 7,375 7,418 -0.6% -0.6% - 28,604 27,954 2.3% 2.3% -
Intl 5,788 6,799 -14.9% -4.5% -10.4% 23,959 23,726 1.0% 11.9% -10.9%
WW 13,163	$ 14,217 -7.4% -2.5% -4.9% 52,563	$ 51,680 1.7% 6.7% -5.0%
See footnotes at end of schedule Page 6 of 17
% Change % Change

-- 7 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
MEDTECH SEGMENT (2,3,5) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 603	$ 483 24.9% 24.9% - 2,169	$ 1,836 18.2% 18.2% -
Intl 495 536 -7.6% 6.2% -13.8% 2,131 2,135 -0.2% 9.9% -10.1%
WW 1,098 1,019 7.8% 15.1% -7.3% 4,300 3,971 8.3% 13.7% -5.4%
ORTHOPAEDICS
US 1,385 1,305 6.1% 6.1% - 5,321 5,126 3.8% 3.8% -
Intl 763 851 -10.4% 0.8% -11.2% 3,267 3,462 -5.6% 3.4% -9.0%
WW 2,148 2,155 -0.4% 4.0% -4.4% 8,587 8,588 0.0% 3.7% -3.7%
HIPS
US 250 227 9.7% 9.7% - 943 878 7.3% 7.3% -
Intl 135 151 -10.4% 0.4% -10.8% 571 602 -5.1% 3.6% -8.7%
WW 385 378 1.7% 6.0% -4.3% 1,514 1,480 2.3% 5.8% -3.5%
KNEES
US 231 208 11.8% 11.8% - 851 787 8.2% 8.2% -
Intl 122 135 -9.5% 1.2% -10.7% 508 538 -5.7% 3.1% -8.8%
WW 354 342 3.4% 7.6% -4.2% 1,359 1,325 2.6% 6.1% -3.5%
TRAUMA
US 470 467 0.7% 0.7% - 1,882 1,819 3.5% 3.5% -
Intl 240 261 -7.9% 3.5% -11.4% 989 1,066 -7.2% 2.6% -9.8%
WW 710 728 -2.4% 1.7% -4.1% 2,871 2,885 -0.5% 3.1% -3.6%
SPINE, SPORTS & OTHER
US 434 403 7.5% 7.5% - 1,645 1,642 0.2% 0.2% -
Intl 265 304 -12.9% -1.5% -11.4% 1,198 1,256 -4.6% 4.3% -8.9%
WW 699 708 -1.3% 3.6% -4.9% 2,843 2,898 -1.9% 1.9% -3.8%
Page 7 of 17
% Change % Change

-- 8 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
SURGERY
US 1,000 986 1.5% 1.5% - 3,897 3,867 0.8% 0.8% -
Intl 1,383 1,527 -9.4% 1.4% -10.8% 5,793 5,945 -2.6% 5.7% -8.3%
WW 2,384 2,513 -5.1% 1.4% -6.5% 9,690 9,812 -1.2% 3.8% -5.0%
ADVANCED
US 456 457 -0.2% -0.2% - 1,784 1,761 1.3% 1.3% -
Intl 653 735 -11.1% -0.4% -10.7% 2,785 2,861 -2.6% 5.3% -7.9%
WW 1,109 1,192 -7.0% -0.3% -6.7% 4,569 4,622 -1.1% 3.8% -4.9%
GENERAL
US 544 528 3.1% 3.1% - 2,113 2,105 0.4% 0.4% -
Intl 731 793 -7.8% 3.0% -10.8% 3,008 3,085 -2.5% 6.2% -8.7%
WW 1,275 1,321 -3.5% 3.0% -6.5% 5,121 5,190 -1.3% 3.8% -5.1%
VISION
US 456 443 3.1% 3.1% - 1,990 1,857 7.2% 7.2% -
Intl 689 728 -5.4% 5.9% -11.3% 2,859 2,831 1.0% 11.1% -10.1%
WW 1,145 1,171 -2.2% 4.8% -7.0% 4,849 4,688 3.4% 9.5% -6.1%
CONTACT LENSES / OTHER
US 343 316 8.6% 8.6% - 1,522 1,398 8.9% 8.9% -
Intl 489 518 -5.6% 7.2% -12.8% 2,022 2,043 -1.0% 10.1% -11.1%
WW 831 833 -0.2% 7.7% -7.9% 3,543 3,440 3.0% 9.6% -6.6%
SURGICAL
US 113 126 -10.7% -10.7% - 468 459 2.0% 2.0% -
Intl 200 211 -5.0% 2.9% -7.9% 837 788 6.2% 13.7% -7.5%
WW 314 338 -7.1% -2.2% -4.9% 1,306 1,248 4.6% 9.4% -4.8%
TOTAL MEDTECH
US 3,445 3,216 7.1% 7.1% - 13,377 12,686 5.4% 5.4% -
Intl 3,331 3,643 -8.6% 2.9% -11.5% 14,050 14,374 -2.3% 6.9% -9.2%
WW 6,776	$ 6,859 -1.2% 4.9% -6.1% 27,427	$ 27,060 1.4% 6.2% -4.8%
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Previously referred to as Medical Devices Page 8 of 17
% Change % Change

-- 9 of 18 --

2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Pharmaceutical
U.S. 7,375	$ 7,418 (0.6) % (0.6) - 28,604	$ 27,954 2.3 % 2.3 -
International 5,788 6,799 (14.9) (4.5) (10.4) 23,959 23,726 1.0 11.9 (10.9)
Worldwide 13,163 14,217 (7.4) (2.5) (4.9) 52,563 51,680 1.7 6.7 (5.0)
COVID-19 Vaccine
U.S. 0 213 * * - 120 634 (81.1) (81.1) -
International 689 1,405 (50.9) (45.0) (5.9) 2,059 1,751 17.6 32.1 (14.5)
Worldwide 689 1,619 (57.4) (52.2) (5.2) 2,179 2,385 (8.6) 2.0 (10.6)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 7,375 7,205 2.4 2.4 - 28,484 27,320 4.3 4.3 -
International 5,099 5,394 (5.5) 6.0 (11.5) 21,900 21,975 (0.3) 10.3 (10.6)
Worldwide 12,474 12,599 (1.0) 3.9 (4.9) 50,384 49,295 2.2 6.9 (4.7)
Worldwide
U.S. 12,516 12,163 2.9 2.9 - 48,580 47,156 3.0 3.0 -
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706 24,804 (4.4) 0.9 (5.3) 94,943 93,775 1.3 6.1 (4.8)
COVID-19 Vaccine
U.S. 0 213 * * - 120 634 (81.1) (81.1) -
International 689 1,405 (50.9) (45.0) (5.9) 2,059 1,751 17.6 32.1 (14.5)
Worldwide 689 1,619 (57.4) (52.2) (5.2) 2,179 2,385 (8.6) 2.0 (10.6)
Worldwide
U.S. 12,516 11,950 4.7 4.7 - 48,460 46,522 4.2 4.2 -
International 10,501 11,236 (6.5) 4.4 (10.9) 44,304 44,868 (1.3) 8.2 (9.5)
Worldwide excluding COVID-19 Vaccine 23,017	$ 23,186 (0.7) % 4.6 (5.3) 92,764	$ 91,390 1.5 % 6.2 (4.7)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Page 9 of 17
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FOURTH QUARTER TWELVE MONTHS
Percent Change Percent Change

-- 10 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 23,706	$ 100.0 24,804	$ 100.0 (4.4)
Cost of products sold 7,765 32.8 7,955 32.1 (2.4)
Gross Profit 15,941 67.2 16,849 67.9 (5.4)
Selling, marketing and administrative expenses 6,512 27.4 7,154 28.9 (9.0)
Research and development expense 3,841 16.2 4,720 19.0 (18.6)
In-process research and development 173 0.7 0 0.0
Interest (income) expense, net (77) (0.3) 47 0.2
Other (income) expense, net 1,207 5.1 9 0.0
Restructuring 84 0.4 83 0.3
Earnings before provision for taxes on income 4,201 17.7 4,836 19.5 (13.1)
Provision for taxes on income 681 2.9 100 0.4 581.0
Net earnings 3,520	$ 14.8 4,736	$ 19.1 (25.7)
Net earnings per share (Diluted) 1.33	$ 1.77	$ (24.9)
Average shares outstanding (Diluted) 2,650.1 2,670.2
Effective tax rate 16.2 % 2.1 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,418	$ 31.3 6,339	$ 25.6 17.0
Net earnings 6,218	$ 26.2 5,678	$ 22.9 9.5
Net earnings per share (Diluted) 2.35	$ 2.13	$ 10.3
Effective tax rate 16.2 % 10.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Page 10 of 17
FOURTH QUARTER
2022 2021

-- 11 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 94,943	$ 100.0 93,775	$ 100.0 1.3
Cost of products sold 31,089 32.7 29,855 31.8 4.1
Gross Profit 63,854 67.3 63,920 68.2 (0.1)
Selling, marketing and administrative expenses 24,765 26.1 24,659 26.3 0.4
Research and development expense 14,603 15.4 14,714 15.7 (0.8)
In-process research and development 783 0.8 900 1.0
Interest (income) expense, net (214) (0.2) 130 0.1
Other (income) expense, net 1,871 2.0 489 0.5
Restructuring 321 0.3 252 0.3
Earnings before provision for taxes on income 21,725 22.9 22,776 24.3 (4.6)
Provision for taxes on income 3,784 4.0 1,898 2.0 99.4
Net earnings 17,941	$ 18.9 20,878	$ 22.3 (14.1)
Net earnings per share (Diluted) 6.73	$ 7.81	$ (13.8)
Average shares outstanding (Diluted) 2,663.9 2,674.0
Effective tax rate 17.4 % 8.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 31,880	$ 33.6 30,464	$ 32.5 4.6
Net earnings 27,038	$ 28.5 26,195	$ 27.9 3.2
Net earnings per share (Diluted) 10.15	$ 9.80	$ 3.6
Effective tax rate 15.2 % 14.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Page 11 of 17
TWELVE MONTHS
2022 2021

-- 12 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported 1.0% (7.4)% (1.2)% (4.4)%
U.S. 10.9% (0.6)% 7.1% 2.9%
International (5.8)% (14.9)% (8.6)% (11.5)%
WW Currency (5.4) (4.9) (6.1) (5.3)
U.S. - - - -
International (9.0) (10.4) (11.5) (10.4)
WW Operational 6.4% (2.5)% 4.9% 0.9%
U.S. 10.9% (0.6)% 7.1% 2.9%
International 3.2% (4.5)% 2.9% (1.1)%
Interventional Solutions
Abiomed (0.5) (0.1)
U.S. (1.0) (0.3)
International 0.0 0.0
All Other Acquisitions and Divestitures 0.0 0.2 0.0 0.1
U.S. 0.1 0.2 (0.2) 0.1
International 0.0 0.1 0.1 0.1
WW Adjusted Operational 6.4% (2.3)% 4.4% 0.8%
U.S. 11.0% (0.4)% 5.9% 2.7%
International 3.2% (4.4)% 3.0% (1.0)%
Page 12 of 17
Note: Percentages are based on actual, non-rounded figures and may not sum.
Adjusted Operational Sales Growth
FOURTH QUARTER 2022 ACTUAL vs. 2021 ACTUAL
Segments

-- 13 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (0.5)% 1.7% 1.4% 1.3%
U.S. 1.3% 2.3% 5.4% 3.0%
International (1.9)% 1.0% (2.3)% (0.6)%
WW Currency (4.1) (5.0) (4.8) (4.8)
U.S. - - - -
International (7.2) (10.9) (9.2) (9.7)
WW Operational 3.6% 6.7% 6.2% 6.1%
U.S. 1.3% 2.3% 5.4% 3.0%
International 5.3% 11.9% 6.9% 9.1%
All Other Acquisitions and Divestitures 0.3 0.1 (0.1) 0.1
U.S. 0.2 0.2 (0.4) 0.0
International 0.5 0.1 0.1 0.2
WW Adjusted Operational 3.9% 6.8% 6.1% 6.2%
U.S. 1.5% 2.5% 5.0% 3.0%
International 5.8% 12.0% 7.0% 9.3%
Page 13 of 17
Adjusted Operational Sales Growth
TWELVE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum.

-- 14 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2022 2021 2022 2021
Net Earnings, after tax- as reported $3,520 $4,736 $17,941 $20,878
Pre-tax Adjustments
Intangible Asset Amortization expense 1,061 1,121 4,305 4,697
Litigation related 262 274 866 2,328
IPR&D 173 - 783 900
Restructuring related 140 140 463 473
Acquisition, integration and divestiture related ¹ 196 26 196 (478)
(Gains)/losses on securities 6 (198) 690 (533)
Medical Device Regulation 2 88 73 296 234
COVID-19 Vaccine related costs 3 821 - 1,474 -
Consumer Health separation costs 470 67 1,089 67
Other - - (7) -
Tax Adjustments
Tax impact on special item adjustments 4 (507) (184) (1,592) (1,281)
Consumer Health separation tax related costs 35 - 494 -
Tax legislation and other tax related (47) (377) 40 (1,090)
Adjusted Net Earnings, after tax $6,218 $5,678 $27,038 $26,195
Average shares outstanding (Diluted) 2,650.1 2,670.2 2,663.9 2,674.0
Adjusted net earnings per share (Diluted) $2.35 $2.13 $10.15 $9.80
Operational adjusted net earnings per share (Diluted) $2.46 $10.70
Notes:
1
2
3
4
Page 14 of 17
Twelve Months Ended
Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition. Acquisition, integration and divestiture related for 2021
primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing
European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May
2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded
only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing
performance which is expected to be completed during 2024.
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses,
associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual
requirements.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted
earnings.
Fourth Quarter

-- 15 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 651 442 3,308 4,306 865 575 (153) (420) (470) (67) 4,201 4,836
% to Sales 17.3% 11.9% 25.1% 30.3% 12.8% 8.4% -0.6% -1.7% -2.0% -0.3% 17.7% 19.5%
Intangible asset amortization expense 84 100 717 761 260 260 - - - - 1,061 1,121
In-process research and development - - 173 - - - - - - - 173 -
Litigation related 72 122 61 (35) 129 187 - - - - 262 274
Loss/(gain) on securities - 1 23 (237) (17) 38 - - - - 6 (198)
Restructuring related 21 28 31 22 88 90 - - - - 140 140
Acquisition, integration and divestiture related - - (104) 5 300 21 - - - - 196 26
Medical Device Regulation - - - - 88 73 - - - - 88 73
COVID-19 Vaccine related costs - - 821 - - - - - - - 821 -
Consumer Health separation costs - - - - - - - - 470 67 470 67
Other - - - - - - - - - - - -
Adjusted Income Before Tax by Segment $ 828 693 5,030 4,822 1,713 1,244 (153) (420) - - 7,418 6,339
% to Sales 22.0% 18.6% 38.2% 33.9% 25.3% 18.1% -0.6% -1.7% 0.0% 0.0% 31.3% 25.6%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 1/24/2023
Page 15 of 17
Q4 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 16 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 2,930 1,573 15,901 17,969 4,607 4,373 (624) (1,072) (1,089) (67) 21,725 22,776
% to Sales 19.6% 10.5% 30.3% 34.8% 16.8% 16.2% -0.7% -1.1% -1.1% -0.1% 22.9% 24.3%
Intangible asset amortization expense 361 414 2,911 3,258 1,033 1,025 - - - - 4,305 4,697
In-process research and development - - 783 - - 900 - - - - 783 900
Litigation related 150 1,603 104 640 612 85 - - - - 866 2,328
Loss/(gain) on securities - (18) 696 (486) (6) (29) - - - - 690 (533)
Restructuring related 91 119 63 76 309 278 - - - - 463 473
Acquisition, integration and divestiture related - - (104) (562) 300 84 - - - - 196 (478)
Medical Device Regulation - - - - 296 234 - - - - 296 234
COVID-19 Vaccine related costs - - 1,474 - - - - - - - 1,474 -
Consumer Health separation costs - - - - - - - 1,089 67 1,089 67
Other - - - - - - (7) - - - (7) -
Adjusted Income Before Tax by Segment $ 3,532 3,691 21,828 20,895 7,151 6,950 (631) (1,072) - - 31,880 30,464
% to Sales 23.6% 24.5% 41.5% 40.4% 26.1% 25.7% -0.7% -1.1% 0.0% 0.0% 33.6% 32.5%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 1/24/2023
Page 16 of 17
Q4 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 17 of 18 --

Fourth Quarter Fourth Quarter
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 1, 2023
Non-GAAP
Cost of products sold 7,765	$ (1,060) (36) (33) (160) (4) - - - 6,472
Selling, marketing and admin expenses 6,512 (9) - (43) 6,460
Research and development expense 3,841 - (46) (114) - 3,681
Other (Income) / Expense 1,207 (1) (262) (20) (196) (6) (547) (423) - - (248)
In-process research and development 173 (173) -
Restructuring 84 (84) -
Provision for taxes on income 681 165 (36) 40 21 5 2 17 199 94 (35) 47 - 1,200
Net Earnings 3,520 896 298 133 119 191 4 71 622 376 35 (47) - 6,218
Fourth Quarter Fourth Quarter
Jan 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 2, 2022
Non-GAAP
Cost of products sold 7,955	$ (1,111) (21) (26) 6,797
Selling, marketing and admin expenses 7,154 (7) 7,147
Research and development expense 4,720 - (40) 4,680
Other (Income) / Expense 9 (10) (274) (36) (26) 198 - (67) - - (206)
In-process research and development - - -
Restructuring 83 (83) -
Provision for taxes on income 100 162 49 - 27 6 (89) 14 - 15 - 377 - 661
Net Earnings 4,736 959 225 - 113 20 (109) 59 - 52 - (377) - 5,678
Twelve Months Twelve Months
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 1, 2023
Non-GAAP
Cost of products sold 31,089	$ (4,292) (82) (109) (456) (4) 26,146
Selling, marketing and admin expenses 24,765 (28) (45) 24,692
Research and development expense 14,603 - (159) (304) 14,140
Other (Income) / Expense 1,871 (13) (866) (60) (196) (690) (714) (1,040) - 7 (1,701)
In-process research and development 783 (783) - - -
Restructuring 321 (321) -
Provision for taxes on income 3,784 667 (125) 178 81 5 166 56 360 206 (494) (40) (2) 4,842
Net Earnings 17,941 3,638 991 605 382 191 524 240 1,114 883 494 40 (5) 27,038
Twelve Months Twelve Months
Jan 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 2, 2022
Non-GAAP
Cost of products sold 29,855	$ (4,661) (86) (85) 25,023
Selling, marketing and admin expenses 24,659 (24) 24,635
Research and development expense 14,714 - (125) 14,589
Other (Income) / Expense 489 (36) (2,328) (135) 478 533 - (67) - - (1,066)
In-process research and development 900 (900) -
Restructuring 252 (252) -
Provision for taxes on income 1,898 667 481 202 86 (98) (116) 44 - 15 - 1,090 - 4,269
Net Earnings 20,878 4,030 1,847 698 387 (380) (417) 190 - 52 - (1,090) - 26,195
(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.
Page 17 of 17
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Consumer Health
separation tax
related costs
Acquisition, integration and
divestiture related
Consumer Health
separation costs
Tax legislation
and other tax
related
Year to Date
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
Consumer Health
separation tax
related costs
Acquisition, integration and
divestiture related (1)
Consumer Health
separation costs
Tax legislation
and other tax
related
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs

-- 18 of 18 --